Iterum Therapeutics Plc (NASDAQ:ITRM) price is hovering higher on current market day and jumping 4.32% above its previous close.
A look at today’s price movement shows that the recent level at last check reads $1.39, with intraday deals fluctuating between $1.35 and $1.52. The company’s 5Y monthly beta was ticking 2.248. Taking into account the 52-week price action we note that the stock hit a 52-week high of $2.50 and 52-week low of $0.71. The stock added 43.56% on its value in the past month.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Iterum Therapeutics Plc, which has a market valuation of $32.92 million, is expected to release its quarterly earnings report on 2024-Nov-14.
Technical indicators in stocks provide crucial insights into market trends, guiding investors with precise entry and exit points based on price movements for informed decision-making.On the technical perspective front, indicators give ITRM a short term outlook of 50% Buy on average. Looking at the stock’s medium term indicators we note that it is averaging as a 50% Sell, while an average of long term indicators are currently assigning the stock as 50% Buy.
Here is a look at the average analyst rating for the stock as represented on a scale of 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock is strong buy or strong sell respectively. Specifically, 1 analysts have assigned ITRM a recommendation rating as follows: 0 rate it as a Hold; 1 advise Buy while 0 analyst(s) assign an Overweight rating. 0 analyst(s) have tagged the Iterum Therapeutics Plc (ITRM) stock as Underweight, with 0 recommending Sell. In general, analysts have rated the stock Buy, a scenario likely to bolster investors out for an opportunity to add to their holdings of the company’s shares.
The overview shows that ITRM’s price is at present 13.15% off the SMA20 and 27.43% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 58.47, with weekly volatility standing at 8.45%. The indicator jumps to 15.87% when calculated based on the past 30 days. Iterum Therapeutics Plc (NASDAQ:ITRM)’s beta value is holding at 2.27, while the average true range (ATR) indicator is currently reading 0.16.
An analysis of the Iterum Therapeutics Plc (NASDAQ:ITRM) stock in terms of its daily trading volume indicates that the 3-month average is 2.37 million. However, this figure increases on the past 10-day timeline to an average of 1.67 million.
Current records show that the company has 22.71M in outstanding shares. The insiders’ percentage holdings are 3.33% of outstanding shares while the percentage share held by institutions stands at 1.47%. The stats also highlight that short interest as of 2024-10-15, stood at 0.21 million shares, which puts the short ratio at the time at 1.16. From this we can glean that short interest is 97.00 of company’s current outstanding shares. Notably, we see that shares short in October fall slightly given the previous month’s figure stood at 0.34 million. But the -26.40% downside, the stock’s price has registered year-to-date as of today’s value, will likely reignite investor interest given the prospect of it rallying even higher.
